NASDAQ:INAB
In8bio, Inc.
In8bio, Inc. reported net income of −$19.4M in fiscal 2025. The diluted share count rose 145.1%.Summary generated from In8bio, Inc.'s SEC filings. Latest annual report filed Mar 12, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−92.5%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+145.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −15 | −29 | −30 | −30 | −19 |
| Net income | −15 | −29 | −30 | −30 | −19 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KEntry into a material agreement
Jun 1, 2026 - 4Insider transaction report
May 29, 2026 - 4Insider transaction report
May 12, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026 - 8-KResults of operations and financial condition
May 7, 2026 - DEF 14AProxy statement
Mar 26, 2026